SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schiffenbauer, J
Right arrow Articles by Simon, L S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiffenbauer, J
Right arrow Articles by Simon, L S
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?

J Schiffenbauer

Food and Drug Administration, CDER, Rockville, MD 20850, USA, schiffenbaue{at}cder.fda.gov

L S Simon

Harvard Medical School, Boston, MA 02115, USA

The study of systemic lupus erythematosus (SLE) is a challenging undertaking. It is difficult to assess outcomes in SLE randomized controlled trials (RCTs), and this is illustrated by the lack of new therapies approved for use in lupus. In a disease that is waxing and waning, and requires constantly changing medications, identifying treatment effects of new therapies may be difficult, and the use of potentially toxic therapies requires a rigorous understandingof the benefit to risk ratio. Some issues that need to be consideredby the investigatorin designingthese studies include:1) should the trial focus on patientswith active or inactive disease; 2) which of the measures of disease activity should be used or should preventionof flares be examined; 3) should the study focus on defined organ specific endpoints or utilize one of the available disease activity indices to identify changes in disease activity; 4) should the trial be a superioritytrial or an equivalencetrial. This review summarizes the critical issues involving the design of studies in lupus and provides the reader with suggestionsand recommendations for considerationbefore embarking on trials in this area.

Key Words: disease activity indices (DAIs) • flare • health related quality of life (HRQOL) • lupus • noninferiority trials • randomized controlled trials (RCTs)

Lupus, Vol. 13, No. 5, 398-405 (2004)
DOI: 10.1191/0961203303lu1033oa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, K.-M. Chow, W. Gang, and P. K.-T. Li
Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis
Rheumatology, November 1, 2008; 47(11): 1678 - 1681.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
Lupus, December 1, 2007; 16(12): 972 - 980.
[Abstract] [PDF]


Home page
LupusHome page
K Mcelhone, J Abbott, and L -S Teh
A review of health related quality of life in systemic lupus erythematosus
Lupus, October 1, 2006; 15(10): 633 - 643.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
R. W.-Y. Chan, F. M.-M. Lai, E. K.-M. Li, L.-S. Tam, K.-M. Chow, P. K.-T. Li, and C.-C. Szeto
Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis
Rheumatology, August 1, 2006; 45(8): 951 - 957.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
R W-Y Chan, F M-M Lai, E K-M Li, L-S Tam, K-Y Chung, K-M Chow, P K-T Li, and C-C Szeto
Urinary mononuclear cell and disease activity of systemic lupus erythematosus
Lupus, May 1, 2006; 15(5): 262 - 267.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
S. Rinaldi, A. Doria, F. Salaffi, M. Ermani, L. Iaccarino, A. Ghirardello, S. Zampieri, P. Sarzi-Puttini, P. F. Gambari, and G. Perini
Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age
Rheumatology, December 1, 2004; 43(12): 1574 - 1579.
[Abstract] [Full Text] [PDF]



Advertisement